Following a warning from the National Health Surveillance Agency (Anvisa) about the uncontrolled use of weight-loss pens, doctors have highlighted another issue regarding these products: the manipulation and illegal sale of injections intended for weight loss. Despite the fact that laboratory manipulation is only permissible under very specific conditions, with a doctor's prescription, and according to Anvisa guidelines, some pharmacies are marketing unauthorized generic products. This raises serious health concerns, as the risks associated with using unregulated drugs can be significant for patients.

Moreover, it is important to note that the patent for the drug tirzepatide belongs to Eli Lilly, the manufacturer of Mounjaro, and no generic medications with the same active ingredient are legally available. The unethical practices of these pharmacies include direct marketing messages sent to doctors from 14 different companies, offering these illegal medications. This poses a substantial violation of regulatory bodies that aim to protect consumer health and maintain the integrity of the pharmaceutical market.

The promotion of illegal weight-loss injections by unlicensed laboratories and pharmacies not only undermines public health but also poses legal implications for the companies involved. Anvisa’s warning aims to increase awareness amongst healthcare professionals and the public about the dangers associated with using these unauthorized products. As scrutiny intensifies, it will be crucial for authorities to enforce regulations to protect consumers effectively and mitigate the risks associated with unapproved medications.